Bouke Catherine de Jong

Bouke Catherine de Jong

Auto-generated profile, based on publicly available information

Bouke Catherine de Jong

Mycobacteriology Unit, Institute of Tropical Medicine

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
SGSebastien Gagneux
Sebastien Gagneux
KDKathryn DeRiemer
Kathryn DeRiemer
TVTran Van
Tran Van
MKMidori Kato-Maeda
Midori Kato-Maeda
BJBouke C. de Jong
Bouke C. de Jong
PSPeter M. Small
Peter M. Small
Mycobacterium tuberculosis remains a major cause of morbidity and mortality worldwide. Studies have reported human pathogens to have geographically structured population genetics, some of which have been linked to ancient human migrations. However, no study has addressed the potential evolutionary consequences of such longstanding human–pathogen associations. Here, we demonstrate that the global population structure of M. tuberculosis is defined by six phylogeographical lineages, each associated with specific, sympatric human populations. In an urban cosmopolitan environment, mycobacterial lineages were much more likely to spread in sympatric than in allopatric patient populations. Tuberculosis cases that did occur in allopatric hosts disproportionately involved high-risk individuals with impaired host resistance. These observations suggest that mycobacterial lineages are adapted to particular human populations. If confirmed, our findings have important implications for tuberculosis control and vaccine development.

31 October 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
DSDavid Stucki
David Stucki
DBDaniela Brites
Daniela Brites
LJLeïla Jeljeli
Leïla Jeljeli
MCMireia Coscollá
Mireia Coscollá
QLQingyun Liu
Qingyun Liu
SGSebastien Gagneux
Sebastien Gagneux
Sebastien Gagneux and colleagues analyze a global collection of Mycobacterium tuberculosis clinical isolates to classify sublineages by phylogeography. They find globally distributed ‘generalist’ and geographically restricted ‘specialist’ sublineages of lineage 4, indicating that different evolutionary strategies were adopted to succeed in various ecological niches. Generalist and specialist species differ in the breadth of their ecological niches. Little is known about the niche width of obligate human pathogens. Here we analyzed a global collection of Mycobacterium tuberculosis lineage 4 clinical isolates, the most geographically widespread cause of human tuberculosis. We show that lineage 4 comprises globally distributed and geographically restricted sublineages, suggesting a distinction between generalists and specialists. Population genomic analyses showed that, whereas the majority of human T cell epitopes were conserved in all sublineages, the proportion of variable epitopes was higher in generalists. Our data further support a European origin for the most common generalist sublineage. Hence, the global success of lineage 4 reflects distinct strategies adopted by different sublineages and the influence of human migration.

10 July 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KAKoen Andries
Koen Andries
CVCristina Villellas
Cristina Villellas
NCNele Coeck
Nele Coeck
KTKim Thys
Kim Thys
TGTom Gevers
Tom Gevers
AKAnil Koul
Anil Koul
Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of multi-drug resistant tuberculosis in decades. In vitro resistance to BDQ was previously shown to be due to target-based mutations. Here we report that non-target based resistance to BDQ, and cross-resistance to clofazimine (CFZ), is due to mutations in Rv0678, a transcriptional repressor of the genes encoding the MmpS5-MmpL5 efflux pump. Efflux-based resistance was identified in paired isolates from patients treated with BDQ, as well as in mice, in which it was confirmed to decrease bactericidal efficacy. The efflux inhibitors verapamil and reserpine decreased the minimum inhibitory concentrations of BDQ and CFZ in vitro, but verapamil failed to increase the bactericidal effect of BDQ in mice and was unable to reverse efflux-based resistance in vivo. Cross-resistance between BDQ and CFZ may have important clinical implications.

23 October 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
CMCorinne S. Merle
Corinne S. Merle
KFKatherine Fielding
Katherine Fielding
OSOmou Bah Sow
Omou Bah Sow
MGMartin Gninafon
Martin Gninafon
MLMame B. Lo
Mame B. Lo
CLChristian Lienhardt
Christian Lienhardt
Shortening the course of treatment for tuberculosis would be a major improvement for case management and disease control. This phase 3 trial assessed the efficacy and safety of a 4-month gatifloxacin-containing regimen for treating rifampin-sensitive pulmonary tuberculosis. We conducted a noninferiority, randomized, open-label, controlled trial involving patients 18 to 65 years of age with smear-positive, rifampin-sensitive, newly diagnosed pulmonary tuberculosis in five sub-Saharan African countries. A standard 6-month regimen that included ethambutol during the 2-month intensive phase was compared with a 4-month regimen in which gatifloxacin (400 mg per day) was substituted for ethambutol during the intensive phase and was continued, along with rifampin and isoniazid, during the continuation phase. The primary efficacy end point was an unfavorable outcome (treatment failure, recurrence, or death or study dropout during treatment) measured 24 months after the end of treatment, with a noninferiority margin of 6 percentage points, adjusted for country. A total of 1836 patients were assigned to the 4-month regimen (experimental group) or the standard regimen (control group). Baseline characteristics were well balanced between the groups. At 24 months after the end of treatment, the adjusted difference in the risk of an unfavorable outcome (experimental group [21.0%] minus control group [17.2%]) in the modified intention-to-treat population (1356 patients) was 3.5 percentage points (95% confidence interval, −0.7 to 7.7). There was heterogeneity across countries (P=0.02 for interaction, with differences in the rate of an unfavorable outcome ranging from −5.4 percentage points in Guinea to 12.3 percentage points in Senegal) and in baseline cavitary status (P=0.04 for interaction) and body-mass index (P=0.10 for interaction). The standard regimen, as compared with the 4-month regimen, was associated with a higher dropout rate during treatment (5.0% vs. 2.7%) and more treatment failures (2.4% vs. 1.7%) but fewer recurrences (7.1% vs. 14.6%). There was no evidence of increased risks of prolongation of the QT interval or dysglycemia with the 4-month regimen. Noninferiority of the 4-month regimen to the standard regimen with respect to the primary efficacy end point was not shown. (Funded by the Special Program for Research and Training in Tropical Diseases and others; ClinicalTrials.gov number, NCT00216385.)

3 January 2011 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
PNPayam Nahid
Payam Nahid
LJLeah G Jarlsberg
Leah G Jarlsberg
IRIrina Rudoy
Irina Rudoy
BJBouke C de Jong
Bouke C de Jong
AUAlon Unger
Alon Unger
CDCharles L Daley
Charles L Daley
Tuberculosis is a leading cause of death worldwide, yet the determinants of death are not well understood. We sought to determine risk factors for mortality during treatment of drug-susceptible pulmonary tuberculosis under program settings.

1 October 2008 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
BJBouke C. de Jong
Bouke C. de Jong
PHPhilip C. Hill
Philip C. Hill
AAAlex Aiken
Alex Aiken
TATimothy Awine
Timothy Awine
MAMartin Antonio
Martin Antonio
RARichard A. Adegbola
Richard A. Adegbola
Background. There is considerable variability in the outcome of Mycobacterium tuberculosis infection. We hypothesized that Mycobacterium africanum was